GOG-0209

Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer

Principal Investigator

David Scott Miller, MD

Status

Disease Site

Gynecologic [GY] Uterine Corpus

Phase

III

Developmental Therapeutics

No

Primary Objective

To determine if the combination of carboplatin and paclitaxel (TC) chemotherapy is therapeutically equivalent to the combination of doxorubicin, cisplatin and paclitaxel (TAP) chemotherapy with regards to survival. 

Patient Population

Patients must have primary Stage III or Stage IV (see FIGO staging—Appendix I) or recurrent endometrial carcinoma (see GOG Pathology Manual IV:1-4) whose potential for cure by radiation therapy or surgery alone or in combination is very poor.  

Target Accrual

1350